Ezra Cohen to TOR Serine-Threonine Kinases
This is a "connection" page, showing publications Ezra Cohen has written about TOR Serine-Threonine Kinases.
Connection Strength
1.479
-
Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck. Oral Oncol. 2015 Apr; 51(4):291-8.
Score: 0.463
-
Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients. Clin Cancer Res. 2012 Sep 01; 18(17):4785-93.
Score: 0.393
-
Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition. Oncogene. 2017 05 11; 36(19):2737-2749.
Score: 0.133
-
A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers. Oncotarget. 2016 Mar 08; 7(10):10696-709.
Score: 0.126
-
Effect of complementary pathway blockade on efficacy of combination enzastaurin and rapamycin. Head Neck. 2011 Dec; 33(12):1774-82.
Score: 0.089
-
A phase I study of sirolimus and bevacizumab in patients with advanced malignancies. Eur J Cancer. 2011 Jul; 47(10):1484-9.
Score: 0.089
-
mTOR: the mammalian target of replication. J Clin Oncol. 2008 Jan 20; 26(3):348-9.
Score: 0.072
-
Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer. Nat Commun. 2021 04 22; 12(1):2383.
Score: 0.045
-
A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2018 08; 82(2):309-317.
Score: 0.037
-
PI3K? is a molecular switch that controls immune suppression. Nature. 2016 11 17; 539(7629):437-442.
Score: 0.033